150 related articles for article (PubMed ID: 17558446)
21. Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation.
Canal CE; Cordova-Sintjago TC; Villa NY; Fang LJ; Booth RG
Eur J Pharmacol; 2011 Dec; 673(1-3):1-12. PubMed ID: 22020288
[TBL] [Abstract][Full Text] [Related]
22. Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment.
Herrick-Davis K; Grinde E; Weaver BA
Eur J Pharmacol; 2007 Jul; 568(1-3):45-53. PubMed ID: 17507008
[TBL] [Abstract][Full Text] [Related]
23. We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.
Cheng J; Kozikowski AP
ChemMedChem; 2015 Dec; 10(12):1963-7. PubMed ID: 26507582
[TBL] [Abstract][Full Text] [Related]
24. Mutagenesis Analysis Reveals Distinct Amino Acids of the Human Serotonin 5-HT
Liu Y; Canal CE; Cordova-Sintjago TC; Zhu W; Booth RG
ACS Chem Neurosci; 2017 Jan; 8(1):28-39. PubMed ID: 27580242
[TBL] [Abstract][Full Text] [Related]
25. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis.
Tuccinardi T; Calderone V; Rapposelli S; Martinelli A
J Med Chem; 2006 Jul; 49(14):4305-16. PubMed ID: 16821790
[TBL] [Abstract][Full Text] [Related]
26. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of serotonin 5-hydroxytryptamine2c receptor function through heterodimerization: receptor dimers bind two molecules of ligand and one G-protein.
Herrick-Davis K; Grinde E; Harrigan TJ; Mazurkiewicz JE
J Biol Chem; 2005 Dec; 280(48):40144-51. PubMed ID: 16195233
[TBL] [Abstract][Full Text] [Related]
28. Computational modeling toward understanding agonist binding on dopamine 3.
Zhao Y; Lu X; Yang CY; Huang Z; Fu W; Hou T; Zhang J
J Chem Inf Model; 2010 Sep; 50(9):1633-43. PubMed ID: 20695484
[TBL] [Abstract][Full Text] [Related]
29. Mutagenesis analysis of the serotonin 5-HT2C receptor and a Caenorhabditis elegans 5-HT2 homologue: conserved residues of helix 4 and helix 7 contribute to agonist-dependent activation of 5-HT2 receptors.
Xie J; Dernovici S; Ribeiro P
J Neurochem; 2005 Jan; 92(2):375-87. PubMed ID: 15663485
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT
Veeramachaneni GK; Thunuguntla VBSC; Bhaswant M; Mathai ML; Bondili JS
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31581577
[TBL] [Abstract][Full Text] [Related]
31. Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies.
Dukat M; Mosier PD; Kolanos R; Roth BL; Glennon RA
J Med Chem; 2008 Feb; 51(3):603-11. PubMed ID: 18201064
[TBL] [Abstract][Full Text] [Related]
32. Investigation of D₁ receptor-agonist interactions and D₁/D₂ agonist selectivity using a combination of pharmacophore and receptor homology modeling.
Malo M; Brive L; Luthman K; Svensson P
ChemMedChem; 2012 Mar; 7(3):483-94, 338. PubMed ID: 22315216
[TBL] [Abstract][Full Text] [Related]
33. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
34. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
Bissantz C; Bernard P; Hibert M; Rognan D
Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
[TBL] [Abstract][Full Text] [Related]
35. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
36. Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis.
Wang YQ; Lin WW; Wu N; Wang SY; Chen MZ; Lin ZH; Xie XQ; Feng ZW
Acta Pharmacol Sin; 2019 Sep; 40(9):1138-1156. PubMed ID: 30814658
[TBL] [Abstract][Full Text] [Related]
37. Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example.
Zeng L; Guan M; Jin H; Liu Z; Zhang L
Chem Biol Drug Des; 2015 Dec; 86(6):1438-50. PubMed ID: 26072970
[TBL] [Abstract][Full Text] [Related]
38. Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.
Renault N; Gohier A; Chavatte P; Farce A
Eur J Med Chem; 2010 Nov; 45(11):5086-99. PubMed ID: 20880612
[TBL] [Abstract][Full Text] [Related]
39. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies.
Masetti M; Cavalli A; Recanatini M
J Comput Chem; 2008 Apr; 29(5):795-808. PubMed ID: 17926340
[TBL] [Abstract][Full Text] [Related]
40. Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain.
Finnema SJ; Stepanov V; Ettrup A; Nakao R; Amini N; Svedberg M; Lehmann C; Hansen M; Knudsen GM; Halldin C
Neuroimage; 2014 Jan; 84():342-53. PubMed ID: 23994452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
